孟鲁司特联合普米克令舒吸入剂治疗小儿哮喘的疗效及对患儿炎性因子的影响

Effect of of Montelukast Combined with Pulmicort Respules Inhalation in Treatment of Pediatric Asthma and its Influence on Inflammatory Factors

目的探讨孟鲁司特与普米克令舒吸入剂联合治疗小儿哮喘的临床疗效及其对炎性因子的影响。方法选取上高县人民医院2019年1月-2021年1月收治的哮喘小儿66例,采用随机数字表法分为对照组与联合治疗组,各33例。对照组予以普米克令舒吸入剂治疗,联合治疗组予以普米克令舒吸入剂联合孟鲁司特治疗。比较两组临床疗效、肺功能[第1 s用力呼气容积(FEV_(1))与用力肺活量(FVC)百分比(FEV_(1)/FVC)、最大呼气流速(PEF)]、免疫功能(CD3^(+)细胞分数、CD4^(+)细胞分数、CD4^(+)/CD8^(+)比值)、血清炎性因子水平[肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、白细胞介素8(IL-8)及白细胞介素17(IL-17)]及日间与夜间症状评分。结果联合治疗组临床疗效优于对照组,差异有统计学意义(P<0.05);联合治疗组FVC、FEV_(1)、FEV_(1)/FVC以及PEF水平均高于对照组,差异有统计学意义(P<0.05);联合治疗组TNF-α、IL-6、IL-8、IL-17水平及日间、夜间症状评分均低于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特与普米克令舒吸入剂联合治疗小儿哮喘的临床疗效确切,能有效改善患儿哮喘症状、肺功能,降低炎性因子水平,值得临床应用。

Objective To investigate the clinical efficacy of montelukast combined with pulmicort respules inhalation in the treatment of pediatric asthma and its effect on inflammatory factors.Methods A total of 66 children with asthma admitted to Shanggao County People's Hospital from January 2019 to January 2021 were selected and divided into a control group and a combined treatment group according to the random number table method,with 33 cases in each group.The control group was treated with pulmicort inhalation,and the combined treatment group was treated with pulmicort inhalation combined with montelukast.The clinical efficacy,pulmonary function[percentage of forced expiratory volume in one second(FEV_(1))and forced vital capacity(FVC)(FEV_(1)/FVC),peak expiratory flow rate(PEF)],immune function(CD3^(+)cell fraction,CD4^(+)cell fraction,CD4^(+)/CD8^(+)ratio),serum inflammatory factor levels[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8)and interleukin-17(IL-17)]and daytime and nighttime symptom scores were compared between the two groups.Results The clinical efficacy of the combined treatment group was better than that of the control group,and the difference was statistically significant(P<0.05).The levels of FVC,FEV_(1),FEV_(1)/FVC and PEF in the combined treatment group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of TNF-α,IL-6,IL-8,IL-17 and daytime and nighttime symptom scores in the combined treatment group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The clinical efficacy of montelukast combined with pulmicort respules inhalation in the treatment of children with asthma is definite,which can effectively improve the asthma symptoms and lung function of children,reduce the level of inflammatory factors,and is worthy of clinical application.